Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2017.10.018 ◽

2018 ◽

Vol 90 ◽

pp. 153-155 ◽

Cited By ~ 6

Author(s):

David Miles ◽

David Cameron ◽

Magalie Hilton ◽

Josep Garcia ◽

Joyce O'Shaughnessy

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

10.1158/0008-5472.sabcs12-p5-18-26 ◽

2012 ◽

Cited By ~ 5

Author(s):

SM Swain ◽

S-B Kim ◽

J Cortes ◽

J Ro ◽

V Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

10.1158/0008-5472.sabcs-09-41 ◽

2009 ◽

Cited By ~ 15

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Dirix ◽

J. Cortés ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30816-4 ◽

2015 ◽

Vol 51 ◽

pp. S287-S288 ◽

Cited By ~ 6

Author(s):

D. Miles ◽

D. Cameron ◽

I. Bondarenko ◽

M. Lyudmila ◽

J.C. Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Results

Download Full-text

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

European Journal of Cancer ◽

10.1016/j.ejca.2016.09.024 ◽

2017 ◽

Vol 70 ◽

pp. 146-155 ◽

Cited By ~ 60

Author(s):

David Miles ◽

David Cameron ◽

Igor Bondarenko ◽

Lyudmila Manzyuk ◽

Juan Carlos Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Biomarker Evaluation

Download Full-text

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2710-z ◽

2013 ◽

Vol 142 (1) ◽

pp. 89-99 ◽

Cited By ~ 39

Author(s):

David Miles ◽

José Baselga ◽

Dino Amadori ◽

Patrapim Sunpaweravong ◽

Vladimir Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Older Patients ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Subgroup Analyses

Download Full-text

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70860-1 ◽

2007 ◽

Vol 5 (4) ◽

pp. 212-213 ◽

Cited By ~ 7

Author(s):

T. Pienkowski ◽

M. Pegram ◽

J. Forbes ◽

V. Valero ◽

W. Eiermann ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Overall Survival Analysis

Download Full-text

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-6084 ◽

2009 ◽

Cited By ~ 4

Author(s):

N. Robert ◽

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-42 ◽

2009 ◽

Cited By ~ 33

Author(s):

A. Brufsky ◽

I. Bondarenko ◽

V. Smirnov ◽

S. Hurvitz ◽

E. Perez ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Cited By ~ 21

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

Download Full-text

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.08.001 ◽

2011 ◽

Vol 2011 ◽

pp. 33-34

Author(s):

J.T. Thigpen

Keyword(s):

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Epidermal Growth ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text